Abstract:Covalent protein kinase inhibitors exploit currently noncatalytic cysteines in the adenosine 5'-triphosphate (ATP)-binding site via electrophiles directly appended to a reversible-inhibitor scaffold. Here, we delineate a path to target solvent-exposed cysteines at a distance >10 Å from an ATP-site-directed core module and produce potent covalent phosphoinositide 3-kinase α (PI3Kα) inhibitors. First, reactive warheads are used to reach out to Cys862 on PI3Kα, and second, enones are replaced with druglike warheads while linkers are optimized. The systematic investigation of intrinsic warhead reactivity (kchem), rate of covalent bond formation and proximity (kinact and reaction space volume Vr), and integration of structure data, kinetic and structural modeling, led to the guided identification of high-quality, covalent chemical probes. A novel stochastic approach provided direct access to the calculation of overall reaction rates as a function of kchem, kinact, Ki, and Vr, which was validated with compounds with varied linker lengths. X-ray crystallography, protein mass spectrometry (MS), and NanoBRET assays confirmed covalent bond formation of the acrylamide warhead and Cys862. In rat liver microsomes, compounds 19 and 22 outperformed the rapidly metabolized CNX-1351, the only known PI3Kα irreversible inhibitor. Washout experiments in cancer cell lines with mutated, constitutively activated PI3Kα showed a long-lasting inhibition of PI3Kα. In SKOV3 cells, compounds 19 and 22 revealed PI3Kβ-dependent signaling, which was sensitive to TGX221. Compounds 19 and 22 thus qualify as specific chemical probes to explore PI3Kα-selective signaling branches. The proposed approach is generally suited to develop covalent tools targeting distal, unexplored Cys residues in biologically active enzymes.

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Identification of CK2α’ selective inhibitors by the screening of an allosteric-kinase-inhibitor-like compound library

Small Molecule Modulators Targeting Protein Kinase CK1 and CK2

Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.

Insights Into The Impact Of Linker Flexibility And Fragment Ionization On The Design Of Ck2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Characterization of the CHK1 allosteric inhibitor binding site.

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

Compounds Designs of CK2α Inhibitors Derived from Virtual Screening Hit Compounds by Computational Chemistry with Crystallography

Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα

Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening.

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

Exploring The Pivotal Role Of The Ck2 Hinge Region Sub-Pocket In Binding With Tricyclic Quinolone Analogues By Computational Analysis

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Highly Selective Aza-Nitrile Inhibitors for Cathepsin K, Structural Optimization and Molecular Modeling